α-Radioimmunotherapy of intraperitoneally growing OVCAR-3 tumors of variable dimensions: Outcome related to measured tumor size and mean absorbed dose

Journal of Nuclear Medicine

Volumn 47, Issue 8, 2006, Pages 1342-1350

  Elgqvist, Jörgen ^a   Andersson, Håkan ^a   Bäck, Tom ^a   Claesson, Ingela ^a   Hultborn, Ragnar ^a   Jensen, Holger ^b   Johansson, Bengt R ^c   Lindegren, Sture ^a   Olsson, Marita ^c,d   Palm, Stig ^a   Warnhammar, Elisabet ^a   Jacobsson, Lars ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b Rigshospitalet   (Denmark)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d CHALMERS UNIVERSITY OF TECHNOLOGY   (Sweden)

Author keywords

Astatine; Dosimetry; MX35; Ovarian cancer; Radioimmunotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY MX35 IMMUNOGLOBULIN F(AB')2 FRAGMENT AT 211; MONOCLONAL ANTIBODY MX35 IMMUNOGLOBULIN F(AB')2 FRAGMENT I 125; RITUXIMAB IMMUNOGLOBULIN F(AB')2 FRAGMENT; RITUXIMAB IMMUNOGLOBULIN F(AB')2 FRAGMENT AT 211; UNCLASSIFIED DRUG; RITUXIMAB;

ADVANCED CANCER; ALPHA RADIATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW; CANCER GROWTH; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; INOCULATION; KIDNEY; MOUSE; NONHUMAN; OVARY CANCER; PERITONEUM; PRIORITY JOURNAL; RADIATION ABSORPTION; RADIATION DOSE; RADIOACTIVITY; RADIOIMMUNOTHERAPY; SCANNING ELECTRON MICROSCOPY; THYROID GLAND; TUMOR BIOPSY; TUMOR VOLUME; ANIMAL; BAGG ALBINO MOUSE; CANCER TRANSPLANTATION; ELECTRON MICROSCOPY; METHODOLOGY; NUDE MOUSE; OVARY TUMOR; SCINTISCANNING; TREATMENT OUTCOME; TUMOR CELL LINE;

ALPHA PARTICLES; ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; MICROSCOPY, ELECTRON; NEOPLASM TRANSPLANTATION; OVARIAN NEOPLASMS; RADIOIMMUNOTHERAPY; TREATMENT OUTCOME;

EID: 33749043460     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Berkenbilt A, Cannistra SA. Advances in the management of epithelial ovarian cancer. J Reprod Med. 2005;50:426-438.
2. Agarawal R, Kaye SB. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer. 2003;3:502-506.
3. Goldenberg DM. Targeted therapy of cancer with radiolabeled antibodies. J Nucl Med. 2002;43:693-713.
4. McQuarrie S, Mercer J, Syme A, Suresh M, Miller G. Preliminary results of nanopharmaceuticals used in the radioimmunotherapy of ovarian cancer. J Pharm Pharm Sci. 2005;7:29-34.
5. Janssen ML, Pels W, Massuger LF, et al. Intraperitoneal radioimmunotherapy in an ovarian carcinoma mouse model: effect of the radionuclide. Int J Gynecol Cancer. 2003;13:607-613.
6. Borchardt PE, Quadri SM, Freedman RS, Vriesendorp HM. Intraperitoneal radioimmunotherapy with human monoclonal IGM in nude mice with peritoneal carcinomatosis. Cancer Biother Radiopharm. 2000;15:53-64.
7. 90Y-biotin? Gynecol Oncol. 2004;93:691-698.
8. Meredith RF, Alvarez RD, Partridge EE, et al. Intraperitoneal radioimmunochemotherapy of ovarian cancer: a phase I study. Cancer Biother Radiopharm. 2001;16:305-315.
9. Mahe MA, Fumoleau P, Fabbro M, et al. A phase II study of intraperitoneal radioimmunotherapy with iodine-131-labeled monoclonal antibody OC-125 in patients with residual ovarian carcinoma. Clin Cancer Res. 1999;5:3249-3252.
10. Epenetos AA, Hird V, Lambert H, Mason P, Coulter C. Long term survival of patients with advanced ovarian cancer treated with intraperitoneal radioimmunotherapy. Int J Gynecol Cancer. 2000;10:44-46.
11. 177Lu-CC49: a phase I/II study. Gynecol Oncol. 1997;65:94-101.
12. 90yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer. Clin Cancer Res. 2002;8:2806-2811.
13. Stewart JSW, Hird V, Snook D, et al. Intraperitoneal yttrium-90-labeled monoclonal antibody in ovarian cancer. J Clin Oncol. 1990;8:1941-1950.
14. Seiden M, Benigno BB. The SMART study investor group, Southeastern Gynecological Oncology: a pivotal phase III trial to evaluate the efficacy and safety of adjuvant treatment with R1549 (yttrium-90-labeled HMFG1 murine monoclonal antibody) in epithelial ovarian cancer (EOC) [abstract]. Proc Am Soc Clin Oncol. 2004; abstract 5008.
15. Andersson H, Elgqvist J, Horvath G, et al. Astatine-211-labeled antibodies for treatment of disseminated ovarian cancer: an overview of results in an ovarian tumor model. Clin Cancer Res. 2003;9:3914-3921.
16. 211At- radioimmunotherapy of subcutaneous human ovarian cancer xenografts: evaluation of RBE of an alpha emitter in vivo. J Nucl Med. 2005;46:2061-2067.
17. 211At-labelled monoclonal antibody MOv18. Anticancer Res. 2000;20:459-462.
18. 211At in nude mice with intraperitoneally growing ovarian cancer xenografts: a long term study. Acta Oncol. 2000;39:741-745.
19. 131I-labelled monoclonal antibody MOv18 in nude mice with intraperitoneal growth of human ovarian carcinoma. Anticancer Res. 2001;21:409-412.
20. 211At-labeled monoclonal antibody MX35. J Nucl Med. 2005;46:1907-1915.
21. Lindegren S, Bäck T, Jensen HJ. Dry-distillation of astatine-211 from irradiated bismuth targets: a time-saving procedure with high recovery yields. Appl Radiat Isot. 2001;55:157-160.
22. Welshinger M, Yin BWT, Lloyd KO. Initial immunochemical characterization of MX35 ovarian cancer antigen. Gynecol Oncol. 1997;67:188-192.
23. Rubin SC, Kostakoglu L, Divgi C, et al. Biodistribution and intraoperative evaluation of radiolabeled monoclonal antibody MX35 in patients with epithelial ovarian cancer. Gynecol Oncol. 1993;51:61-66.
24. Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994;83:435-445.
25. Lindegren S, Andersson H, Bäck T, Jacobsson L, Karlsson B, Skarnemark G. High-efficiency astatination of antibodies using N-iodosuccinimide as the oxidizing agent in labeling of N-succinimidyl 3-(trimethylstannyl) benzoate. Nucl Med Biol. 2001;28:33-39.
26. Hamilton TC, Young RC, McKoy WM, et al. Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors. Cancer Res. 1983;43:5379-5389.
27. Lindmo T, Boven E, Cuttitta F, Fedorko J, Bunn PA. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods. 1984;72:77-89.
28. Friedman PL, Ellisman MH. Enhanced visualization of peripheral nerve and sensory receptors in the scanning electron microscope using cryofracture and osmium-thiocarbohydrazide-osmium impregnation. J Neurocytol. 1981;10:111-131.
29. Palm S, Humm JL, Rundqvist R, Jacobsson L. Microdosimetry of astatine-211 single-cell irradiation: role of daughter polonium-211 diffusion. Med Phys. 2004;31:218-225.
30. ICRU. Stopping Powers and Ranges for Protons and Alpha Particles. Publication 49. Bethesda, MD: International Commission on Radiation Units and Measurements; 1993.
31. 60Co irradiation in nude mice. J Nucl Med. 2005;46:464-471.
32. Horak E, Hartmann F, Garmestani K, et al. Radioimmunotherapy targeting of HER2/neu oncoprotein on ovarian tumor using lead-212-DOTA-AE1. J Nucl Med. 1997;38:1944-1950.